To date, the US Food and Drug Administration has approved ICIs targeting three different molecules (CTLA-4, PD-1, and its ligand, PD-L1) for use in humans, improving CM patients' prognosis [35, 36]. The gene discussed is CTLA4; the disease is cutaneous mastocytosis.